541 related articles for article (PubMed ID: 24534415)
1. Molecular actions and clinical pharmacogenetics of lithium therapy.
Can A; Schulze TG; Gould TD
Pharmacol Biochem Behav; 2014 Aug; 123():3-16. PubMed ID: 24534415
[TBL] [Abstract][Full Text] [Related]
2. Genetic influences on response to mood stabilizers in bipolar disorder: current status of knowledge.
Rybakowski JK
CNS Drugs; 2013 Mar; 27(3):165-73. PubMed ID: 23378337
[TBL] [Abstract][Full Text] [Related]
3. The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis.
Machado-Vieira R; Manji HK; Zarate CA
Bipolar Disord; 2009 Jun; 11 Suppl 2(Suppl 2):92-109. PubMed ID: 19538689
[TBL] [Abstract][Full Text] [Related]
4. Molecular effects of lithium.
Quiroz JA; Gould TD; Manji HK
Mol Interv; 2004 Oct; 4(5):259-72. PubMed ID: 15471909
[TBL] [Abstract][Full Text] [Related]
5. [Guidelines for the prescription of mood stabilizers for adolescents: A literature review].
Munch G; Godart N
Encephale; 2017 Oct; 43(5):464-470. PubMed ID: 27871720
[TBL] [Abstract][Full Text] [Related]
6. The Pharmacogenomics of Bipolar Disorder study (PGBD): identification of genes for lithium response in a prospective sample.
Oedegaard KJ; Alda M; Anand A; Andreassen OA; Balaraman Y; Berrettini WH; Bhattacharjee A; Brennand KJ; Burdick KE; Calabrese JR; Calkin CV; Claasen A; Coryell WH; Craig D; DeModena A; Frye M; Gage FH; Gao K; Garnham J; Gershon E; Jakobsen P; Leckband SG; McCarthy MJ; McInnis MG; Maihofer AX; Mertens J; Morken G; Nievergelt CM; Nurnberger J; Pham S; Schoeyen H; Shekhtman T; Shilling PD; Szelinger S; Tarwater B; Yao J; Zandi PP; Kelsoe JR
BMC Psychiatry; 2016 May; 16():129. PubMed ID: 27150464
[TBL] [Abstract][Full Text] [Related]
7. Lithium, Stress, and Resilience in Bipolar Disorder: Deciphering this key homeostatic synaptic plasticity regulator.
Machado-Vieira R
J Affect Disord; 2018 Jun; 233():92-99. PubMed ID: 29310970
[TBL] [Abstract][Full Text] [Related]
8. Lithium pharmacodynamics and pharmacogenetics: focus on inositol mono phosphatase (IMPase), inositol poliphosphatase (IPPase) and glycogen sinthase kinase 3 beta (GSK-3 beta).
Serretti A; Drago A; De Ronchi D
Curr Med Chem; 2009; 16(15):1917-48. PubMed ID: 19442155
[TBL] [Abstract][Full Text] [Related]
9. Lithium Pharmacogenetics: Where Do We Stand?
Pisanu C; Melis C; Squassina A
Drug Dev Res; 2016 Nov; 77(7):368-373. PubMed ID: 27633500
[TBL] [Abstract][Full Text] [Related]
10. Potential mechanisms of action of lithium in bipolar disorder. Current understanding.
Malhi GS; Tanious M; Das P; Coulston CM; Berk M
CNS Drugs; 2013 Feb; 27(2):135-53. PubMed ID: 23371914
[TBL] [Abstract][Full Text] [Related]
11. Neuroprotective effects of lithium: implications for the treatment of Alzheimer's disease and related neurodegenerative disorders.
Forlenza OV; De-Paula VJ; Diniz BS
ACS Chem Neurosci; 2014 Jun; 5(6):443-50. PubMed ID: 24766396
[TBL] [Abstract][Full Text] [Related]
12. Lithium - past, present, future.
Rybakowski JK
Int J Psychiatry Clin Pract; 2020 Nov; 24(4):330-340. PubMed ID: 33169645
[TBL] [Abstract][Full Text] [Related]
13. Genetics of Lithium Response in Bipolar Disorder.
Papiol S; Schulze TG; Alda M
Pharmacopsychiatry; 2018 Sep; 51(5):206-211. PubMed ID: 29579760
[TBL] [Abstract][Full Text] [Related]
14. Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs.
Gould TD; Manji HK
Neuropsychopharmacology; 2005 Jul; 30(7):1223-37. PubMed ID: 15827567
[TBL] [Abstract][Full Text] [Related]
15. New Advances in the Pharmacology and Toxicology of Lithium: A Neurobiologically Oriented Overview.
Bortolozzi A; Fico G; Berk M; Solmi M; Fornaro M; Quevedo J; Zarate CA; Kessing LV; Vieta E; Carvalho AF
Pharmacol Rev; 2024 May; 76(3):323-357. PubMed ID: 38697859
[TBL] [Abstract][Full Text] [Related]
16. A new avenue for lithium: intervention in traumatic brain injury.
Leeds PR; Yu F; Wang Z; Chiu CT; Zhang Y; Leng Y; Linares GR; Chuang DM
ACS Chem Neurosci; 2014 Jun; 5(6):422-33. PubMed ID: 24697257
[TBL] [Abstract][Full Text] [Related]
17. The International Consortium on Lithium Genetics (ConLiGen): an initiative by the NIMH and IGSLI to study the genetic basis of response to lithium treatment.
Schulze TG; Alda M; Adli M; Akula N; Ardau R; Bui ET; Chillotti C; Cichon S; Czerski P; Del Zompo M; Detera-Wadleigh SD; Grof P; Gruber O; Hashimoto R; Hauser J; Hoban R; Iwata N; Kassem L; Kato T; Kittel-Schneider S; Kliwicki S; Kelsoe JR; Kusumi I; Laje G; Leckband SG; Manchia M; Macqueen G; Masui T; Ozaki N; Perlis RH; Pfennig A; Piccardi P; Richardson S; Rouleau G; Reif A; Rybakowski JK; Sasse J; Schumacher J; Severino G; Smoller JW; Squassina A; Turecki G; Young LT; Yoshikawa T; Bauer M; McMahon FJ
Neuropsychobiology; 2010; 62(1):72-8. PubMed ID: 20453537
[TBL] [Abstract][Full Text] [Related]
18. The Role of Pharmacogenomics in Bipolar Disorder: Moving Towards Precision Medicine.
Pisanu C; Heilbronner U; Squassina A
Mol Diagn Ther; 2018 Aug; 22(4):409-420. PubMed ID: 29790107
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder.
Chiu CT; Wang Z; Hunsberger JG; Chuang DM
Pharmacol Rev; 2013 Jan; 65(1):105-42. PubMed ID: 23300133
[TBL] [Abstract][Full Text] [Related]
20. Lithium in the treatment of bipolar disorder: pharmacology and pharmacogenetics.
Alda M
Mol Psychiatry; 2015 Jun; 20(6):661-70. PubMed ID: 25687772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
